Allen Kaplan to United States
This is a "connection" page, showing publications Allen Kaplan has written about United States.
Connection Strength
0.010
-
A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria. J Allergy Clin Immunol. 2011 Sep; 128(3):567-73.e1.
Score: 0.010